This protocol is directed at patients with invasive pulmonary aspergillosis who present with severe disease or whose condition has not responded adequately — a subset that warrants a specific, intensified treatment strategy.
Severe or refractory invasive pulmonary aspergillosis represents a high-risk clinical situation. This population requires an approach that goes beyond standard monotherapy, and combination antifungal strategies are specifically reserved for patients meeting these criteria.
Evidence supports combination antifungal therapy — using a triazole together with an echinocandin — in patients with severe or refractory disease. This dual-agent approach is not indicated for all presentations and is targeted to this specific population.
DOI: 10.1183/16000617.0114-2022